No Data
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
Zhihong Hong Kong Shareholder Equity Disclosure | January 22
Hong Kong Stock Shareholder Equity Disclosure | January 22
ZHONGZHIPHARM (03737.HK) was acquired by the Chairman and Executive Director Lai Zhitian, increasing the Shareholding by 0.28 million shares.
On January 22, according to the latest equity disclosure information from the Stock Exchange, from January 20 to January 21, 2025, ZHONGZHIPHARM (03737.HK) was acquired by Chairman and Executive Director Lai Zhitian, who purchased a total of 280,000 shares at an average price of HKD 0.93-0.96 per share, involving approximately HKD 0.2628 million. After the Shareholding increase, Lai Zhitian's latest shareholding amount is 564,367,800 shares, with the shareholding ratio rising from 65.32% to 65.35%.
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.
① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
